Haixi New Medicine: The oral medication project HXP056 for wAMD has completed recruitment for Phase I clinical research and started Phase II research.

Haixi Pharmaceuticals Announcement: The company's innovative drug project HXP056, which is expected to become the world's first oral drug for hemorrhagic retinal diseases, has started recruiting patients with wet age-related macular degeneration in China in early July 2025. The recruitment of all patients in the single dose escalation and multiple dose escalation stages of the first phase clinical trial has been completed, and dose-limiting toxicity evaluation and pharmacokinetic data collection will be completed after four weeks of continuous dosing. Preliminary efficacy evaluation is also ongoing. In the fourth quarter of 2025, the company has initiated a phase II clinical study with dose escalation.